• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

6个家庭中罕见疾病低磷性佝偻病的多代遗传及临床特征:病例系列

Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series.

作者信息

Kannu Peter, Khan Aliya A, Francis Mira, Adachi Jonathan D

机构信息

University of Alberta, 8613 114 Street, Edmonton, AB T6G 1C9, Canada.

McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.

出版信息

Bone Rep. 2025 Jul 15;26:101857. doi: 10.1016/j.bonr.2025.101857. eCollection 2025 Sep.

DOI:10.1016/j.bonr.2025.101857
PMID:40746945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12311441/
Abstract

Family mapping is a useful tool for tracking the inheritance of rare inherited diseases, including hypophosphatasia (HPP), through generations. We show the inheritance of HPP in 6 affected families, describing genetic variants, biochemical hallmarks, and clinical manifestations among family members. Mapping families with HPP is warranted in clinical practice to better understand monitoring needs for potentially affected individuals over time, since manifestations of HPP can arise throughout a patient's lifespan.

摘要

家系图谱是追踪罕见遗传病(包括低磷血症(HPP))跨代遗传的有用工具。我们展示了6个受影响家系中HPP的遗传情况,描述了家庭成员中的基因变异、生化特征和临床表现。在临床实践中绘制HPP家系图谱是有必要的,以便更好地了解潜在受影响个体随时间推移的监测需求,因为HPP的表现可能在患者的整个生命周期中出现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/79d10110fa77/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/298f8f09e562/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/f5e6c01a9b70/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/24510d0825fc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/1203fb1e04f1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/79d10110fa77/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/298f8f09e562/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/f5e6c01a9b70/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/24510d0825fc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/1203fb1e04f1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e4/12311441/79d10110fa77/gr5.jpg

相似文献

1
Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series.6个家庭中罕见疾病低磷性佝偻病的多代遗传及临床特征:病例系列
Bone Rep. 2025 Jul 15;26:101857. doi: 10.1016/j.bonr.2025.101857. eCollection 2025 Sep.
2
Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval.关于阿法骨化醇酶在低磷性骨软化症中有效性的临床研究及真实世界证据的关键经验总结:获批后10年
Adv Ther. 2025 Jul 25. doi: 10.1007/s12325-025-03309-1.
3
Mobility and Quality of Life in Children with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement.接受阿法骨化醇治疗的儿童期起病低磷酸酯酶症患儿的活动能力和生活质量:英国管理式准入协议的结果
Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03225-4.
4
Case Report: Suboptimal response to standard-dose asfotase alfa in perinatal hypophosphatasia indicates a need for individualized dosing.病例报告:围产期低磷酸酯酶症患者对标准剂量阿法骨化醇反应欠佳,提示需个体化给药。
Front Endocrinol (Lausanne). 2025 Jun 18;16:1587807. doi: 10.3389/fendo.2025.1587807. eCollection 2025.
5
Disease burden by variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry.全球HPP注册中心非危及生命型低磷血症患者按变异数量划分的疾病负担。
J Med Genet. 2025 Mar 20;62(4):249-257. doi: 10.1136/jmg-2024-110383.
6
Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase's role in vitamin B metabolism.吡哆醇激发试验反映了儿童低磷酸酶血症的严重程度,从而检验了组织非特异性碱性磷酸酶在维生素 B 代谢中的作用。
Bone. 2024 Apr;181:117033. doi: 10.1016/j.bone.2024.117033. Epub 2024 Feb 1.
7
Preclinical evaluation of the efficacy and safety of adeno-associated virus 8-tissue-nonspecific alkaline phosphatase-D10 in Alpl-/- and AlplPrx1/Prx1 mouse models for the treatment of early and late-onset hypophosphatasia.腺相关病毒8-组织非特异性碱性磷酸酶-D10在Alpl-/-和AlplPrx1/Prx1小鼠模型中治疗早发性和晚发性低磷酸酯酶症的疗效和安全性的临床前评估
J Bone Miner Res. 2025 Apr 21;40(4):463-477. doi: 10.1093/jbmr/zjaf005.
8
Loeys-Dietz Syndrome洛伊斯-迪茨综合征
9
Clinical presentation of adults with persistently low alkaline phosphatase activity: a retrospective multicentre, cross-sectional study in Germany.成年人体内碱性磷酸酶活性持续偏低的临床表现:德国一项回顾性多中心横断面研究
BMJ Open. 2025 Jul 1;15(7):e097235. doi: 10.1136/bmjopen-2024-097235.
10
Differential Pregnancy Decisions in a Woman With a Recurrent Prenatal Diagnosis of Hypophosphatasia.一名复发性产前诊断为低磷酸酯酶症的女性的差异化妊娠决策
Cureus. 2025 Jun 29;17(6):e87005. doi: 10.7759/cureus.87005. eCollection 2025 Jun.

本文引用的文献

1
New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP Registry.从全球 HPP 注册中心看成骨不全症低磷酸酯酶症患者中 ALPL 基因突变的新认识。
Am J Med Genet A. 2024 Nov;194(11):e63781. doi: 10.1002/ajmg.a.63781. Epub 2024 Jun 17.
2
Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults.低磷酸酯酶症的诊断:儿童和成人的现状和拟议的诊断标准。
Osteoporos Int. 2024 Mar;35(3):431-438. doi: 10.1007/s00198-023-06844-1. Epub 2023 Nov 20.
3
The Global ALPL gene variant classification project: Dedicated to deciphering variants.
全球 ALPL 基因变异分类项目:致力于破解变异。
Bone. 2024 Jan;178:116947. doi: 10.1016/j.bone.2023.116947. Epub 2023 Oct 26.
4
Serum alkaline phosphatase can be elevated in patients with hypophosphatasia due to liver disease.血清碱性磷酸酶在因肝病而患有低磷酸酶血症的患者中可能会升高。
Eur J Med Genet. 2023 Nov;66(11):104866. doi: 10.1016/j.ejmg.2023.104866. Epub 2023 Oct 13.
5
Multigenerational case examples of hypophosphatasia: Challenges in genetic counseling and disease management.低磷酸酯酶症的多代病例示例:遗传咨询与疾病管理中的挑战
Mol Genet Metab Rep. 2020 Oct 21;25:100661. doi: 10.1016/j.ymgmr.2020.100661. eCollection 2020 Dec.
6
Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia.通过蛋白质建模进行大规模的体外功能测试和新型变异评分,为低磷酸酶血症中碱性磷酸酶活性提供了深入的见解。
Hum Mutat. 2020 Jul;41(7):1250-1262. doi: 10.1002/humu.24010. Epub 2020 Mar 18.
7
Hypophosphatasia: Biological and Clinical Aspects, Avenues for Therapy.低磷酸酯酶症:生物学与临床方面及治疗途径
Clin Biochem Rev. 2020 Feb;41(1):13-27. doi: 10.33176/AACB-19-00031.
8
Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a systematic literature review.低磷酸酯酶症患者疾病临床表现的发生频率和年龄:系统文献回顾。
Orphanet J Rare Dis. 2019 Apr 25;14(1):85. doi: 10.1186/s13023-019-1062-0.
9
Hypophosphatasia.低磷酸酯酶症。
Metabolism. 2018 May;82:142-155. doi: 10.1016/j.metabol.2017.08.013. Epub 2017 Sep 20.
10
Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.阿法特酶治疗低磷酸酯酶症患者的监测指导。
Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25.